Examples of using Overall data in English and their translations into Danish
{-}
-
Medicine
-
Official
-
Colloquial
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Overall data show that the Belgian performance is average.
A number of layers andtheir sequence depend on overall data about each layer in a borehole.
The overall data stored on it will erase and create new memory location to store data freshly.
Make it an easy transition with the help of Coolmuster Mobile Transfer,which empowers you with the ability to transfer overall data.
If we take a broader range of safety indicators, overall data show that railway safety standards in Europe are generally very high.
Make it an easy transition with the help of Coolmuster Mobile Transfer,which empowers you with the ability to transfer overall data….
The Applicant considered that the overall data demonstrate that spacer use results in the same high extent of in vitro equivalence as inhaler testing without this device.
Make it an easy transition with the help of Coolmuster Mobile Transfer,which empowers you with the ability to transfer overall data between two mobile phones.
Children and adolescents Overall data from clinical trials indicate an increased risk of suicidal and hostility related behaviours in the paediatric population 7-17 years old.
It is equipped with the advanced error correction code engine for enhancing the reliability of the card as well as the overall data integrity during read and write.
During its January 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that a marketing authorisation should be granted.
Created with the latest technology of the time, this SanDisk SDSDXPA -064 G-AFFP captures Full HD video.It is equipped with the advanced error correction code engine for enhancing the reliability of the card as well as the overall data integrity during read and write.
During its June 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Lansopon.
Such checks shall focus on overall data relating to that period for the manufacturers and buyers concerned, and on at least 10% of all the transactions and utilizations which have taken place.
At that time, no one, not the government, the WFP or the NGOs, were able,due to the lack of precise overall data, to assess whether it was a slightly more difficult crisis than in previous years or a serious food crisis.
During its July 2008 meeting, the CVMP, in light of the overall data submitted and the scientific discussion within the Committee, adopted by consensus an opinion concluding that the assessment of the risk presented by toltrazuril and its major metabolite, toltrazuril sulfone, to terrestrial plants and to groundwater demonstrated that use of products containing toltrazuril is acceptable.
During its April 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Crestor 5 mg or Crestor 10 mg as start dose.
During their September 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Glucomed and associated names for the relief of symptoms in mild to moderate osteoarthritis of the knee, that there was no objection for the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State.
Time budgets by socio-occupational group and sex;- normal pattern of the year(number of days worked;length of holidays; overall data on absenteeism if possible);- average length of working week and working day;- data on"constrained time"(working time+ journey time);- phases of life: a statutory retirement age; average actual age; trends; b ages of entry into the labour market.
During the June 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Cardoreg 4 mg prolonged release tablets and associated names, that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
During their May 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Ceftriaxone Tyrol Pharma and associated names, that the objections raised by United Kingdom should.
During their April 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the objections raised by Spain could be agreed and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
During its 12-15 September 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee was of the opinion that a marketing authorisation should be granted subject to certain conditions considered essential for the safe and effective use of the medicinal product.
During their July 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Lisonorm, that the objections raised by Czech Republic and Latvia should not prevent the granting of a Marketing Authorisation.
During their January 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the objections that triggered the Article 29 Referral, should not prevent the granting of a Marketing Authorisation for Alendronate HEXAL and associated names.
During their April 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the objections that triggered the Article 29 Referral should not prevent the granting of a Marketing Authorisation for Oracea and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
During their January 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Ciprofloxacin Hikma and associated names, that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
During their June 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Activelle and associated names, that the objections raised by France and Germany should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
During its January 2004 meeting, the CPMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that although, the development of the product and the presence of avoidable impurities have raised important quality concerns, there appears to be no safety concerns arising from the impurity profile in this product, based on the toxicology studies provided by the company.
During their November 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Menitorix, that the objections raised by Greece, Poland and Spain should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.